Skip to content

Covidreab study: pulmonary rehabilitation on physical capacity, functional capacity, and quality of life in post-covid-19: randomized, controlled double-blinded clinical trial

Covidreab study: pulmonary rehabilitation on physical capacity, functional capacity, and quality of life in post-covid-19

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
REBEC
Registry ID
RBR-3t9pkzt
Enrollment
Unknown
Registered
2021-07-01
Start date
2021-08-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

A pulmonary rehabilitation (PR) program associated with the use of noninvasive ventilation (NIV) will be conducted in individuals with COVID-19 after the severe form (post-COVID-19 syndrome). 100 indi
E02.041.625.591

Sponsors

Universidade Federal do Amazonas
Lead Sponsor
Universidade Federal do Amazonas
Collaborator

Eligibility

Age
30 Years to 65 Years

Inclusion criteria

Inclusion criteria: Clinically stable individuals, residing in Manaus must have been diagnosed with COVID-19 by the polymerase chain reaction method (RT-PCR) for SARS-CoV-2, remained hospitalized and had discharged from the hospital. In addition, volunteers must present a pre-hospitalization medical history of clinical stability in the 4 months before hospitalization for COVID-19 and perception of dyspnea II and III by the Medical Research Council (MRC).

Exclusion criteria

Exclusion criteria: Volunteers undergoing pulmonary rehabilitation 6 months before the start of the study, pregnant women, previous medical history of respiratory diseases (COPD, asthma, idiopathic pulmonary fibrosis), arterial O2 saturation (SpO2) = 88% at rest, hypertension uncontrolled, cardiovascular (heart failure, hypertension, transplantation, and surgeries), history of use and abuse of illicit drugs, alcoholics, smokers, pacemakers and/or implantable defibrillators, oncologic, metabolic (diabetes) and decompensated, chronic-degenerative kidneys in progression and osteoarticular and cognitive that prevent the performance of the physical exercise. In addition, individuals who present claustrophobia to the use of the NIV mask for training or performing the cardiopulmonary test will be excluded.

Design outcomes

Primary

MeasureTime frame
Improved V?O2 through cardiopulmonary test, distance walked in the 6-minute walk test, and quality of life through SF-36 values

Secondary

MeasureTime frame
Improvement of spirometric variables, cytokine quantification, arterial endothelial function, HbO2 consumption behavior, HHb production, total hemoglobin and tissue saturation index during exercise, heart rate variability, the sequelae prevalence, the maintenance time of the primary and secondary clinical outcomes and, the number of admissions and deaths within 12 months after hospital discharge.

Countries

Brazil

Contacts

Public ContactGuilherme Arêas
Guilhermepta@ufam.edu.br+55-92-993560935

Outcome results

None listed

Source: REBEC (via WHO ICTRP) · Data processed: Feb 6, 2026